Loading stock data…
XGN
$4.31+0.11 (+2.62%)
After Hours$4.31+0.00 (+0.00%)· Last close Jun 9
Exagen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exagen Inc. in the Healthcare sector is trading at $4.31 with a market capitalization of $110M. Wall Street consensus targets $8.67 (6 analysts), implying a +101.1% move over the next 12 months. The stock is currently near its 52-week low of $2.59, remaining 31.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +101.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.31
Potential Downside
0%
Whystock Fair Value$4.31
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$109.69M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-139.73%
Volume
Today's trading volume
299,485
Recent News
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts
A week ago, Exagen Inc. ( NASDAQ:XGN ) came out with a strong set of quarterly numbers that could potentially lead to a...
Exagen (XGN) Q1 2026 Earnings Transcript
John Aballi: Good morning, everyone, and thank you for joining us. Today, we reported record first quarter revenue of $17.3 million, up 12% year-over-year and with continued improvement in profitability metrics as we execute our plan. Autoimmune disease is still a category where patients often struggle to get clear answers and clinicians lack the tools to diagnose and treat with confidence in a timely manner.
Exagen Inc. Q1 2026 Earnings Call Summary
Moby summary of Exagen Inc.'s Q1 2026 earnings call
Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...
Exagen Inc (XGN) reports a 12% revenue increase and reaffirms its full-year guidance, despite facing operational hurdles and financial challenges.